Skip to main content

Peer Review reports

From: Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Original Submission
27 Nov 2020 Submitted Original manuscript
27 Mar 2021 Reviewed Reviewer Report - Cristiano Resende
27 Apr 2021 Reviewed Reviewer Report - Daniel J. Booser
18 May 2021 Author responded Author comments - Xiaosong Chen
Resubmission - Version 2
18 May 2021 Submitted Manuscript version 2
29 May 2021 Author responded Author comments - Xiaosong Chen
Resubmission - Version 3
29 May 2021 Submitted Manuscript version 3
9 Jun 2021 Author responded Author comments - Xiaosong Chen
Resubmission - Version 4
9 Jun 2021 Submitted Manuscript version 4
4 Jul 2021 Reviewed Reviewer Report - Cristiano Resende
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
9 Jul 2021 Editorially accepted
13 Jul 2021 Article published 10.1186/s12885-021-08555-4

You can find further information about peer review here.

Back to article page